OncoMatch/Clinical Trials/NCT05445011
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Is NCT05445011 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Fludarabine + Cyclophosphamide + TAA05 Cell for acute myeloid leukemia.
Treatment: Fludarabine + Cyclophosphamide + TAA05 Cell — This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
creatinine ≤ 1.5 uln
Liver function
total bilirubin ≤ 2 × uln; alt and ast ≤ 2.5 × uln; for the patients with alt and ast abnormalities caused by disease which researchers judge (e.g. liver infiltrates or bile duct obstruction), the indicators of which can be relaxed to ≤5× uln
Cardiac function
left ventricular ejection fraction ≥ 50% and echocardiography does not reveal pericardial effusions and ecg does not reveal clinically significant abnormal bands
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05445011 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FLT3?
Yes, FLT3 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages